Aevi Genomic Medicine Current Ratio 2012-2019 | GNMX

Aevi Genomic Medicine current ratio from 2012 to 2019. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Aevi Genomic Medicine Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2019-03-31 $0.01B $0.00B 1.95
2018-12-31 $0.01B $0.00B 2.82
2018-09-30 $0.02B $0.01B 3.13
2018-06-30 $0.02B $0.01B 4.05
2018-03-31 $0.03B $0.01B 5.77
2017-12-31 $0.04B $0.00B 8.36
2017-09-30 $0.02B $0.01B 2.32
2017-06-30 $0.02B $0.01B 4.56
2017-03-31 $0.03B $0.01B 5.54
2016-12-31 $0.04B $0.01B 7.20
2016-09-30 $0.05B $0.01B 8.71
2016-06-30 $0.06B $0.00B 13.95
2016-03-31 $0.05B $0.00B 12.57
2015-12-31 $0.05B $0.00B 13.77
2015-09-30 $0.02B $0.01B 1.84
2015-06-30 $0.02B $0.00B 9.33
2015-03-31 $0.03B $0.00B 18.08
2014-12-31 $0.03B $0.00B 9.24
2014-09-30 $0.02B $0.00B 6.03
2014-06-30 $0.02B $0.00B 7.36
2014-03-31 $0.02B $0.00B 6.87
2013-12-31 $0.02B $0.00B 7.50
2013-09-30 $0.03B $0.00B 7.75
2013-06-30 $0.03B $0.00B 13.24
2013-03-31 $0.03B $0.00B 12.38
2012-12-31 $0.01B $0.00B 2.97
2012-09-30 $0.01B $0.00B 4.45
2012-06-30 $0.01B $0.00B 4.96
2012-03-31 $0.00B $0.00B 2.23
2011-12-31 $0.01B $0.00B 2.97
2011-09-30 $0.01B $0.00B 3.79
2011-06-30 $0.01B $0.00B 5.20
2011-03-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.013B $0.000B
Aevi Genomic Medicine Inc. is focused on genomic medicine. The Company focuses on translating genetic discoveries into novel therapies. Its product candidates include AEVI-001 and AEVI-002 which are in clinical trial stage. Aevi Genomic Medicine Inc., formerly known as Medgenics Inc., is based in WAYNE, United States.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $42.880B 7.81
Mylan (MYL) United Kingdom $9.443B 4.13
Teva Pharmaceutical Industries (TEVA) Israel $8.593B 3.37
Bausch Health Cos (BHC) Canada $8.382B 5.73
Dr Reddy's Laboratories (RDY) India $5.986B 22.39
Supernus Pharmaceuticals (SUPN) United States $1.616B 16.15
Voyager Therapeutics (VYGR) United States $1.021B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.971B 54.32
Homology Medicines (FIXX) United States $0.854B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.752B 1.12
Akorn (AKRX) United States $0.602B 0.00
CymaBay Therapeutics (CBAY) United States $0.486B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.441B 0.00
Assembly Biosciences (ASMB) United States $0.335B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.281B 0.00
Sol-Gel Technologies (SLGL) Israel $0.175B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.151B 0.00
Acasti Pharma (ACST) Canada $0.079B 0.00
Agile Therapeutics (AGRX) United States $0.063B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.055B 0.00
Teligent (TLGT) United States $0.035B 0.00
Evoke Pharma (EVOK) United States $0.014B 0.00